GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Gross-Profit-to-Asset %

Astellas Pharma (TSE:4503) Gross-Profit-to-Asset % : 45.05% (As of Mar. 2025)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Astellas Pharma's annualized Gross Profit for the quarter that ended in Mar. 2025 was 円1,529,744 Mil. Astellas Pharma's average Total Assets over the quarter that ended in Mar. 2025 was 円3,395,587 Mil. Therefore, Astellas Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 45.05%.


Astellas Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Astellas Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Gross-Profit-to-Asset % Chart

Astellas Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.74 45.30 51.38 43.52 45.25

Astellas Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.36 41.83 42.21 48.47 45.05

Competitive Comparison of Astellas Pharma's Gross-Profit-to-Asset %

For the Drug Manufacturers - General subindustry, Astellas Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Gross-Profit-to-Asset % falls into.


;
;

Astellas Pharma Gross-Profit-to-Asset % Calculation

Astellas Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2025 )/( (Total Assets (A: Mar. 2024 )+Total Assets (A: Mar. 2025 ))/ count )
=1563117/( (3569603+3339544)/ 2 )
=1563117/3454573.5
=45.25 %

Astellas Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=1529744/( (3451630+3339544)/ 2 )
=1529744/3395587
=45.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Astellas Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines